Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats.
Wistar rats
diabetic neuropathy
molsidomine
streptozotocin
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
19
12
2020
accepted:
02
02
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
3
3
2022
Statut:
epublish
Résumé
Diabetic neuropathy is a disorder that affects various regions of the nervous system and there is no specific treatment available for it. This study evaluated the protective effect of molsidomine in diabetic neuropathy in rats. Diabetes was induced in male Wistar rats by administrating streptozotocin (52 mg/kg ip). Diabetic rats were treated with molsidomine 5 mg/kg po and 10 mg/kg po. After 8 weeks of treatment, motor coordination, mechanical allodynia, mechanical hyperalgesia, nerve conduction velocity, and glycosylated hemoglobin were assessed. Thereafter, animals were killed and the sciatic nerve was isolated for measurement of reduced glutathione and lipid peroxidation, and histopathological analysis. Treatment with molsidomine significantly improved motor coordination, paw withdrawal threshold, mechanical threshold, and nerve conduction velocity. Furthermore, molsidomine treatment also reduced malondialdehyde levels and prevented depletion of reduced glutathione in the sciatic nerve homogenate. Histopathology revealed that molsidomine treatment maintained normal architecture of the sciatic nerve. The results of our study strengthen the alternative use of molsidomine in diabetic neuropathy.
Identifiants
pubmed: 34557650
doi: 10.1002/ame2.12162
pii: AME212162
pmc: PMC8446713
doi:
Substances chimiques
Molsidomine
D46583G77X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
243-248Informations de copyright
© 2021 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Déclaration de conflit d'intérêts
There is no conflict of interest.
Références
Neurosciences (Riyadh). 2015 Apr;20(2):115-23
pubmed: 25864063
Behav Brain Res. 2008 May 16;189(1):65-74
pubmed: 18243354
Neuropharmacology. 2009 Sep;57(4):403-8
pubmed: 19591853
N Engl J Med. 1984 Feb 9;310(6):341-6
pubmed: 6690962
Nitric Oxide. 2016 Dec 30;61:1-9
pubmed: 27677584
Indian J Otolaryngol Head Neck Surg. 2014 Sep;66(3):314-9
pubmed: 25032121
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cell Biochem Funct. 2007 May-Jun;25(3):251-8
pubmed: 16397909
J Assoc Physicians India. 2014 Jan;62(1):24-7
pubmed: 25327088
Postgrad Med J. 2006 Feb;82(964):95-100
pubmed: 16461471
Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:89-92
pubmed: 22271730
Postgrad Med J. 2002 Sep;78(923):541-2
pubmed: 12357015
Cancer Res. 2008 Aug 1;68(15):6425-34
pubmed: 18676868
Curr Eye Res. 2017 May;42(5):803-809
pubmed: 27897441
Diabetologia. 1987 Aug;30(8):653-8
pubmed: 2820821
J Neurotrauma. 2012 Mar 20;29(5):898-904
pubmed: 21682605
Diabetes Care. 2004 Jul;27(7):1668-73
pubmed: 15220244
Clinics (Sao Paulo). 2012 Dec;67(12):1419-25
pubmed: 23295596
Cardiovasc Diabetol. 2011 Nov 23;10:105
pubmed: 22107602
Nat Clin Pract Neurol. 2007 Jun;3(6):331-40
pubmed: 17549059
Pharmacol Rep. 2018 Apr;70(2):309-315
pubmed: 29477039
Biochim Biophys Acta. 1979 Jan 4;582(1):67-78
pubmed: 760819
Biotech Histochem. 2017;92(1):68-77
pubmed: 28166419